Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00649012 | Food Study of Pioglitazone HCl Tablets 45 mg to Actos® Tablets 45 mg | PHASE1 | COMPLETED | 40 | — | — | Mar 1, 2003 | Mar 1, 2003 | Apr 24, 2024 | 1 | United States |
| NCT00649558 | Fasting Study of Pioglitazone HCl Tablets 45 mg and Actos® Tablets 45 mg | PHASE1 | COMPLETED | 36 | — | — | Feb 1, 2003 | Mar 1, 2003 | Apr 24, 2024 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Pioglitazone HCl Tablets 45 mg |
| 2 | ACTIVE_COMPARATOR | Actos® Tablets 45 mg |
| Name | Type | Description |
|---|---|---|
| Pioglitazone HCl Tablets 45 mg | DRUG | 45mg, single dose fed |
| Actos® Tablets 45 mg | DRUG | 45mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...